6Ruddy S;Harris ED Jr;Sledge CB.Kelley's Textbook of Rheumatology,2001.
7Argov Z.Drug-induced myopathies,2000(05).
8Ucar M;Mjomdal T;Dahlqvist R.HMGCOA reduclase-inhibitor and myotoxicity,2000(06).
9Pastermask RC;Smith SC Jr;Bairey-merz CN.ACC/AHA/NHLBI clinical advisory on the use and safety of statins,2002(08).
10Staffa JA;Chang J;Green L.Cerivastatin and reports of fatal rhabdomyolysis,2002(07).
二级参考文献46
1Moyle G. Toxicity antiretroviral nucleoside and nucleotide analogues. Is mitochondrial toxicity the only mechanism?[J]. Drag Saf, 2000, 23(6): 467.
2Besser R, Treese N, Bohl J, Clinical, neurophysiologic and biopsy findings in neurotoxic amiodarone syndrome [J]. Med Klin (Munich), 1994, 89(7): 367.
3Toussirot E, Wendling D. Fibromyalgia developed after administration of gonadotrophin-releasing hormone analogue[J]. Clin Rheumatol, 2001, 20(2): 150.
4Saag KG, Koehnke R, Caldwell JR, etal. Low dose longterm corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events[J]. Am.J.Med, 1994,96(2): 115.
5Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity[J]. J Rheumatol, 2000, 27(12): 2927.
6Older SA, Finbloom DS, Pezeshkpour GH. Colchicine myoneuropathy and renal dysfunction [J]. Ann Rheum Dis, 1992, 51(12): 1343.
7VIctor M, Sieb JP. Myopathies due to drugs, toxins, and nutritional deficiency [A]. In: Myology (2nd ed) [M].Engel AG, Franzinl Armstong C (eds), McGraw-Hill,1997: 1697-1725.
8Ucar M, Mjomdal T, Dahlqvist R. HMG COA reductaseinhibitors and myotoxicity[J]. Drug Safety, 2000, 22(6):441.
9Hargreaves I, Heales S. Statiusandmyopathy[J]. Lancet,2002, 359(2): 711.
10England JD, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG COA reductase inhibitors-simvastatin and pravastatin [J]. Aust N ZJ Med, 1995, (4)25: 374.
